reglab/housing_qa huggingface dataset:
MD. Health - General Code Ann. §  20-1502 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 15 - Down Syndrome Information|Section 20-1502 - General Consideration

    (a)    The Department shall identify up–to–date, evidence–based, written information about Down syndrome that:        (1)    Has been reviewed by medical experts and national and local Down syndrome organizations;        (2)    Is designed for use by an expectant parent who receives a prenatal test result for Down syndrome or a parent of a child who receives a diagnosis of Down syndrome;        (3)    Is culturally and linguistically appropriate for potential recipients of the information; and        (4)    Includes:            (i)    Information addressing physical, developmental, educational, and psychosocial outcomes, life expectancy, clinical course, and intellectual and functional development and treatment options for individuals with Down syndrome; and            (ii)    Contact information for national and local Down syndrome education and support programs and services, including information hotlines, resource centers, and clearinghouses.    (b)    The Department shall:        (1)    Provide the information identified by the Department under subsection (a) of this section to health care facilities and health care providers that provide prenatal care, postnatal care, or genetic counseling to expectant parents who receive a prenatal test result for Down syndrome and parents of a child diagnosed with Down syndrome; and        (2)    Make available the information identified by the Department under subsection (a) of this section on the Department’s website.    (c)    (1)    On receipt of a positive test result from a test for Down syndrome, a health care facility or health care provider may provide to the expectant parent who receives a prenatal test result for Down syndrome or the parent of the child diagnosed with Down syndrome the written information provided or made available by the Department under subsection (b) of this section.        (2)    The information provided under this subsection shall be culturally and linguistically appropriate for the recipient of the information.
MD. Health - General Code Ann. §  20-1602 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 16 - Nondiscrimination in Access to Anatomical Gifts and Organ Transplantation|Section 20-1602 - Construction of Subtitle

    This subtitle may not be construed to require a covered entity to make a referral or recommendation for or perform a medically inappropriate organ transplant.
MD. Health - General Code Ann. §  20-1603 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 16 - Nondiscrimination in Access to Anatomical Gifts and Organ Transplantation|Section 20-1603 - Legislative Findings

    The General Assembly finds that:        (1)    A mental or physical disability does not diminish an individual’s right to health care;        (2)    The federal Americans with Disabilities Act prohibits discrimination against individuals with disabilities, yet many individuals with disabilities still experience discrimination in accessing critical health care services;        (3)    In other states nationwide, individuals with mental and physical disabilities have historically been denied life–saving organ transplants based on assumptions that their lives are less worthy, that they are incapable of complying with posttransplantation medical requirements, or that they lack adequate support systems to ensure compliance with posttransplantation medical requirements;        (4)    Although organ transplant centers must consider medical and psychosocial criteria when determining if a patient is suitable to receive an organ transplant, transplant centers that participate in Medicare, the Maryland Medical Assistance Program, and other federally funded programs are required to use patient selection criteria that result in a fair and nondiscriminatory distribution of organs; and        (5)    State residents in need of organ transplants are entitled to assurances that they will not encounter discrimination on the basis of a disability.
MD. Health - General Code Ann. §  20-1604 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 16 - Nondiscrimination in Access to Anatomical Gifts and Organ Transplantation|Section 20-1604 - Applicability

    This subtitle applies to each part of the organ transplant process.
MD. Health - General Code Ann. §  20-1605 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 16 - Nondiscrimination in Access to Anatomical Gifts and Organ Transplantation|Section 20-1605 - General Consideration

    (a)    A covered entity may not solely on the basis of an individual’s disability:        (1)    Consider a qualified individual ineligible to receive an anatomical gift or organ transplant;        (2)    Deny medical and other services related to organ transplantation, including evaluation, surgery, counseling, and posttransplantation treatment and services;        (3)    Refuse to refer the individual to a transplant center or a related specialist for the purpose of evaluation or receipt of an organ transplant;        (4)    Refuse to place a qualified individual on an organ transplant waiting list; or        (5)    Place a qualified individual at a lower–priority position on an organ transplant waiting list than the position at which the qualified individual would have been placed if not for the disability.    (b)    (1)    Subject to paragraph (2) of this subsection, a covered entity may take an individual’s disability into account when making treatment or coverage recommendations or decisions, solely to the extent that the disability has been found by a physician, following an individualized evaluation of the individual, to be medically significant to the provision of the anatomical gift.        (2)    If an individual has the necessary support system to assist the individual in complying with posttransplantation medical requirements, a covered entity may not consider the individual’s inability to independently comply with the posttransplantation medical requirements to be medically significant for the purposes of paragraph (1) of this subsection.    (c)    A covered entity shall make reasonable modifications in policies, practices, or procedures, when the modifications are necessary to  allow an individual with a disability access to services, including transplantation–related counseling, information, coverage, or treatment, unless the covered entity can demonstrate that making the modifications would fundamentally alter the nature of the services.    (d)    A covered entity shall take such steps as may be necessary to ensure that an individual with a disability is not denied services, including transplantation–related counseling, information, coverage, or treatment, due to the absence of auxiliary aids and services, unless the covered entity can demonstrate that taking the steps would fundamentally alter the nature of the services being offered or would result in an undue burden.
MD. Health - General Code Ann. §  20-1606 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 16 - Nondiscrimination in Access to Anatomical Gifts and Organ Transplantation|Section 20-1606 - Judicial Remedies

    (a)    If a covered entity violates this subtitle, the affected individual may bring an action in the appropriate circuit court for injunctive or other equitable relief.    (b)    In an action brought under subsection (a) of this section, the circuit court shall:        (1)    Schedule a hearing as soon as possible; and        (2)    Apply the same standards in rendering a judgment in the action as would be applied in an action brought in federal court under the federal Americans with Disabilities Act.
MD. Health - General Code Ann. §  20-1701 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 17 - Lyme Disease Information|Section 20-1701 - General Consideration

    (a)    A health care provider licensed in the State who draws the blood of a patient to perform a laboratory test for Lyme disease or a medical laboratory, as defined in § 17–201 of this article, that performs a laboratory test for the presence of Lyme disease shall provide the following written notice to the patient at the time the patient’s blood is drawn:    “Your health care provider has ordered a laboratory test for the presence of Lyme disease for you. Current laboratory testing for Lyme disease can be problematic and standard laboratory tests often result in false negative and false positive results and, if done too early, you may not have produced enough antibodies to be considered positive because your immune response requires time to develop antibodies. If you are tested for Lyme disease and the results are negative, this does not necessarily mean you do not have Lyme disease. If you continue to experience unexplained symptoms, you should contact your health care provider and inquire about the appropriateness of retesting or initial or additional treatment.”.    (b)    If the Department finds significant differences between the content of the notice required by subsection (a) of this section and current medical evidence on Lyme disease testing, the Department may adopt regulations that change the content of the notice.    (c)    The Department shall provide written notice to the Senate Finance Committee and the House Health and Government Operations Committee before submitting any proposed regulation under subsection (b) of this section to the Maryland Register for publication.    (d)    The provision by a health care provider or medical laboratory of the notice required by subsection (a) of this section may not be the sole basis for a cause of action.
MD. Health - General Code Ann. §  20-1801 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 18 - Maternal Mental Health|Section 20-1801 - Identification and Dissemination of Information About Perinatal Mood and Anxiety Disorders

    (a)    (1)    In this section the following words have the meanings indicated.        (2)    (i)    “Health care facility” means a facility or an office where health or medical care is provided to patients by a health care provider.            (ii)    “Health care facility” includes a hospital and a limited service hospital.        (3)    “Health care provider” means a person who is licensed, certified, or otherwise authorized under the Health Occupations Article to provide health or medical care in the ordinary course of business or practice of a profession.        (4)    “Hospital” has the meaning stated in § 19–301 of this article.        (5)    “Limited service hospital” has the meaning stated in § 19–301 of this article.    (b)    The Department, in consultation with stakeholders, shall identify up–to–date, evidence–based, written information about perinatal mood and anxiety disorders that:        (1)    Has been reviewed by medical experts and national and local organizations specializing in maternal mental health;        (2)    Is designed for use by health care providers and pregnant and postpartum women and their families;        (3)    Is culturally and linguistically appropriate for potential recipients of the information; and        (4)    Includes:            (i)    Information addressing:                1.    The signs and symptoms of perinatal mood and anxiety disorders;                2.    Perinatal medication usage;                3.    Risk factors of perinatal mood and anxiety disorders, including perinatal loss and high–risk pregnancy;                4.    How and when to screen for symptoms of perinatal mood and anxiety disorders;                5.    Brief intervention strategies; and                6.    Evidence–based psychosocial treatments; and            (ii)    Contact information for national and local maternal mental health programs and services.    (c)    The Department shall:        (1)    Provide the information identified by the Department under subsection (b) of this section to health care facilities and health care providers that provide prenatal care, labor and delivery services, and postnatal care to expectant parents; and        (2)    Make the information identified by the Department under subsection (b) of this section available on the Department’s website.
MD. Health - General Code Ann. §  20-1802 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 18 - Maternal Mental Health|Section 20-1802 - Training Programs

    (a)    The Department, in collaboration with MedChi, The Maryland State Medical Society, the Maryland Nurses Association, the Maryland Affiliate of the American College of Nurse Midwives, the Maryland Psychological Association, and any other health professional association or public health entity in the State identified by the Department, shall identify and develop training programs that improve early identification of postpartum depression and perinatal mood and anxiety disorders.    (b)    The programs developed under subsection (a) of this section shall include continuing medical education programs developed by organizations that are accredited by the Accreditation Council for Continuing Medical Education.
MD. Health - General Code Ann. §  20-1901 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 19 - Subcutaneous Implanting of Identification Device|Section 20-1901 - Definitions

    (a)    In this subtitle the following words have the meanings indicated.    (b)    (1)    “Identification device” means an item, an application, or a product that is passively or actively capable of transmitting personal information, including devices using radio frequency technology.        (2)    “Identification device” does not include an item, an application, or a product that is used in the diagnosis, monitoring, treatment, or prevention of a health condition.    (c)    “Personal information” includes the following data elements to the extent that the data elements are used alone or in conjunction with other information used to identify an individual:        (1)    First or last name;        (2)    Address;        (3)    Telephone number;        (4)    E–mail, Internet Protocol, or website address;        (5)    Date of birth;        (6)    Driver’s license number or identification card number;        (7)    Bank, credit card, or other financial account number;        (8)    Any unique personal identifier contained or encoded on a health insurance, health benefit, or benefit card or record issued in conjunction with a government–supported aid program;        (9)    Religion;        (10)    Ethnicity or nationality;        (11)    Photograph;        (12)    Fingerprint or other biometric identifier;        (13)    Social Security number; and        (14)    Any other unique personal identifier.    (d)    “Require, coerce, or compel” includes the use of physical violence, threat, intimidation, retaliation, the conditioning of any private or public benefit, including employment, promotion, or other employment benefit, and any other means to cause a reasonable individual of ordinary susceptibilities to acquiesce when the individual otherwise would not.    (e)    “Subcutaneous” means existing, performed, or introduced under or on the skin.
MD. Health - General Code Ann. §  20-1902 (2021)
2021 Maryland Statutes|Health - General|Title 20 - Miscellaneous Health Provisions|Subtitle 19 - Subcutaneous Implanting of Identification Device|Section 20-1902 - Subcutaneous Implanting of an Identification Device

    (a)    A person or an agent, a representative, or a designee of the State or a local government may not require, coerce, or compel an individual to undergo the subcutaneous implanting of an identification device.    (b)    (1)    An individual who is implanted with a subcutaneous identification device in violation of subsection (a) of this section may file a civil action in the circuit court in the county where the violation occurred.        (2)    If the court finds that the person or agent, representative, or designee of the State or a local government violated subsection (a) of this section, the court may:            (i)    Assess against the defendant:                1.    A civil penalty not exceeding $10,000; and                2.    An additional civil penalty not exceeding $1,000 for each day after the day of implantation that the violation continues until corrected; and            (ii)    Award the plaintiff:                1.    Compensatory damages;                2.    Injunctive relief;                3.    Reasonable attorney’s fees and litigation expenses, including expert witness fees and expenses; or                4.    Any other appropriate relief.        (3)    In addition to the damages or relief awarded under paragraph (2) of this subsection, the court may award the plaintiff punitive damages on a finding of proof of the defendant’s malice, oppression, fraud, or duress inflicted in requiring, coercing, or compelling the plaintiff to undergo the subcutaneous implanting of an identification device.    (c)    (1)    Except as provided in paragraph (2) of this subsection, an action brought under subsection (b) of this section shall be filed within 3 years after the date on which the identification device was implanted.        (2)    If a defendant induces the plaintiff to delay the filing of the action or the plaintiff delays the filing due to threats made by the defendant that caused the plaintiff duress, the defendant may not assert the limitation specified under paragraph (1) of this subsection.    (d)    The remedies provided by this section are in addition to any other statutory, legal, or equitable remedies that may be available and are not intended to be prerequisite to or exclusive of any other remedies.    (e)    The provisions of this section shall be liberally construed in the protection of privacy and bodily integrity.
MD. Health - General Code Ann. §  21-2A-02 (2021)
2021 Maryland Statutes|Health - General|Title 21 - Food, Drugs, and Cosmetics|Subtitle 2A - Prescription Drug Monitoring Program|Section 21-2A-02 - Program

    (a)    There is a Prescription Drug Monitoring Program in the Department.    (b)    The mission of the Program is to:        (1)    Assist prescribers, pharmacists, and public health professionals in:            (i)    The identification and prevention of prescription drug abuse; and            (ii)    The identification and investigation of unlawful prescription drug diversion; and        (2)    Promote a balanced use of prescription monitoring data to assist appropriate law enforcement activities while preserving the professional practice of health care providers and the access of patients to optimal pharmaceutical care.    (c)    To carry out its mission, the Program shall monitor the prescribing and dispensing of all Schedule II, Schedule III, Schedule IV, and Schedule V controlled dangerous substances by all prescribers and dispensers in the State.
MD. Health - General Code Ann. §  21-2A-03 (2021)
2021 Maryland Statutes|Health - General|Title 21 - Food, Drugs, and Cosmetics|Subtitle 2A - Prescription Drug Monitoring Program|Section 21-2A-03 - Implementation and Operation; Prescription Monitoring Data

    (a)    The Department shall implement the Program, subject to the availability of funds.    (b)    The Secretary may:        (1)    Assign responsibility for the operation of the Program to any unit in the Department;        (2)    Contract with any qualified person for the efficient and economical operation of the Program; and        (3)    Identify and publish a list of monitored prescription drugs that have a low potential for abuse by individuals.    (c)    Except as provided in subsection (d) of this section, each dispenser shall submit prescription monitoring data to the Program by electronic means, in accordance with regulations adopted by the Secretary.    (d)    The Secretary, for good cause shown, may authorize a dispenser to submit prescription monitoring data by an alternative form of submission.    (e)    The Secretary, in consultation with the Maryland Health Care Commission and the Board, shall:        (1)    Determine the appropriate technology to support the operation of the Program; and        (2)    Educate dispensers, prescribers, pharmacists, prescriber delegates, pharmacist delegates, and consumers about the purpose and operation of the Program.    (f)    (1)    The Secretary shall grant a waiver to a pharmacy that dispenses medications to an inpatient hospice from reporting to the Program prescription monitoring data for hospice inpatients if:            (i)    The pharmacy demonstrates how it will distinguish hospice inpatients from other consumers receiving medications from the pharmacy; and            (ii)    The pharmacy agrees that it will be subject to onsite, unannounced inspections by the Department to verify its reporting of the prescription data of consumers who are not hospice inpatients.        (2)    A waiver granted under this subsection may remain in effect for up to 2 years.        (3)    The Secretary may establish an application process for a pharmacy to apply for a waiver under this subsection.
MD. Health - General Code Ann. §  21-2A-04 (2021)
2021 Maryland Statutes|Health - General|Title 21 - Food, Drugs, and Cosmetics|Subtitle 2A - Prescription Drug Monitoring Program|Section 21-2A-04 - Regulations

    (a)    The Secretary, in consultation with the Board, shall adopt regulations to carry out this subtitle.    (b)    The regulations adopted by the Secretary shall:        (1)    Specify the prescription monitoring data required to be submitted under § 21–2A–03 of this subtitle;        (2)    Specify the electronic or other means by which information is to be submitted:            (i)    Without unduly increasing the workload and expense on dispensers; and            (ii)    In a manner as compatible as possible with existing data submission practices of dispensers;        (3)    Specify that the information be submitted by dispensers once every 24 hours;        (4)    Specify that the Program:            (i)    Shall provide the information technology software to dispensers necessary to upload prescription drug monitoring data to the Program; and            (ii)    May not impose any fees or other assessments on prescribers or dispensers to support the operation of the Program;        (5)    Identify the mechanism by which prescription monitoring data are disclosed to a person, in accordance with § 21–2A–06 of this subtitle;        (6)    Identify the circumstances under which a person may disclose prescription monitoring data received under the Program;        (7)    Specify the process for the Program’s review of prescription monitoring data and reporting of:            (i)    Possible misuse or abuse of a monitored prescription drug under § 21–2A–06(c) of this subtitle; or            (ii)    A possible violation of law or possible breach of professional standards under § 21–2A–06(d) of this subtitle;        (8)    Establish requirements for Program retention of prescription monitoring data for 3 years; and        (9)    Require that:            (i)    Confidential or privileged patient information be kept confidential; and            (ii)    Records or information protected by a privilege between a health care provider and a patient, or otherwise required by law to be held confidential, be filed in a manner that, except as otherwise provided in § 21–2A–06 of this subtitle, does not disclose the identity of the person protected.